Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.38 |
| ▸ | GCGR | P47871 | 2/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27985279 | 0.89 | MAPK1 (0.40) | MAPK1MGAMGAASIMGAM2 | |
| SCHEMBL6647087 | 0.83 | NISCH (0.48) | MAPK1GAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28279252 | 0.80 | ALDH1A1 (0.46) | KDM4EMGAMGAASIMGAM2 | |
| SCHEMBL3635215 | 0.80 | NPC1 (0.44) | MAPK1KDM4EGAANPC1RAB9A | |
| SCHEMBL797826 | 0.80 | TNKS (0.40) | MAPK1GAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10554989 | 0.80 | GAA (0.44) | MGAMGAASIMGAM2NPC1 | |
| SCHEMBL29346840 | 0.79 | NPC1 (0.47) | MAPK1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL49612 | 0.79 | GAA (0.52) | KDM4EGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29843542 | 0.79 | ERCC1 (0.43) | MAPK1 | |
| SCHEMBL28856158 | 0.79 | ERCC1 (0.43) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111922553-A | Copper surface protective agent for advanced wafer packaging field and preparation method thereof | 深圳市创智成功科技有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-107971655-B | High-heat-resistance organic solder flux and application thereof | 永星化工(上海)有限公司 | 2019-12-27 | — | — | CN | claimed |
| CN-111922553-A | Copper surface protective agent for advanced wafer packaging field and preparation method thereof | 深圳市创智成功科技有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107971655-B | High-heat-resistance organic solder flux and application thereof | 永星化工(上海)有限公司 | 2019-12-27 | — | — | CN | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | MAPK1 920/4885KDM4E 3779/4885MGAM 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.